12. Acute myeloid leukemia commentary

  1. Ross Pinkerton MB, BCh, BaO, MD Executive Director, Division of Oncology2,
  2. Ananth Shankar MD, FRCPCH Consultant in Paediatric and Adolescent Oncology3 and
  3. Katherine K. Matthay BA, MD Mildred V. Strouss Professor of Translational Oncology, Director, Pediatric Hematology-Oncology4
  1. Robert J. Arceci

Published Online: 8 MAY 2013

DOI: 10.1002/9781118625309.ch12

Evidence-Based Pediatric Oncology

Evidence-Based Pediatric Oncology

How to Cite

Arceci, R. J. (2013) Acute myeloid leukemia commentary, in Evidence-Based Pediatric Oncology (eds R. Pinkerton, A. Shankar and K. K. Matthay), John Wiley & Sons, Ltd, Oxford. doi: 10.1002/9781118625309.ch12

Editor Information

  1. 2

    Royal Children's Hospital, Children's Health Queensland, Brisbane, QLD, Australia

  2. 3

    University College London Hospitals NHS Foundation Trust London, UK

  3. 4

    Department of Pediatrics, UCSF School of Medicine and, UCSF Benioff Children's Hospital, San Francisco, CA, USA

Author Information

  1. Johns Hopkins University, Baltimore, MD, USA

Publication History

  1. Published Online: 8 MAY 2013
  2. Published Print: 20 MAY 2013

ISBN Information

Print ISBN: 9780470659649

Online ISBN: 9781118625309

SEARCH

Keywords:

  • acute myeloid leukemia (AML);
  • allogeneic transplantation;
  • hematopoietic stem cell transplantation (HSCT);
  • postremission therapy;
  • remission

Summary

An ever increasing number of molecular signatures are continuing to demonstrate the profound heterogeneity that characterizes acute myeloid leukemia (AML). The first significant advance in inducing remission in patients with AML included the combination of 7 days of cytosine arabinoside (ARAC) at 100 mg/m2 by continuous infusion along with three initial days of daunomycin at 45 mg/m2